Novo Nordisk

Belkins
At Novo Nordisk, we are driving change to defeat diabetes and other serious chronic conditions. Diabetes poses one of today’s biggest global health challenges. We work for a future where fewer people get diabetes, everyone with diabetes is diagnosed, and everyone who is diagnosed receives adequate treatment and can live a life with as few limitations as possible.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

ROCHE AND ILLUMINA FORGE GENOMICS ALLIANCE FOR CANCER TESTING

pharma news | January 14, 2020

news image

Roche missed out on acquiring next-generation sequencing (NGS) specialist Illumina via a hostile takeover a few years back, but has compensated for that with a 15-year alliance focusing on cancer genomics. The new deal comes after Illumina called off a $1.2 billion merger agreement with another NGS player – Pacific Biosciences or PacBio – after concluding it would be unlikely to make it past antitrust regulators in the US and UK. Illumina is thought to have around 80% of the DNA sequ...

Read More

POINT-OF-CARE TOOLS IN PHARMACY TAKE OFF

Managed Healthcare Executive | March 02, 2020

news image

New point-of-care (POC) tools that promote communication between providers and patients are establishing themselves as next generation shared decision-making solutions, especially when it comes to medications and issues of insurance coverage, price, and out-of-pocket costs. “When compared to traditional shared decision-making tools, there’s an increased emphasis not just on improving measures such as medication adherence by involving the patient in his or her own care but also on usi...

Read More

OBI PHARMA ANNOUNCES OBI-999 PRESENTATION AT 2020 WORLD ADC DIGITAL MEETING

OBI Pharma | September 14, 2020

news image

OBI Pharma, Inc, a leader in Glycosphingolipid Immuno-Oncology therapeutics targeting the Globo Series antigens (Globo H and SSEA-4) and chemotherapeutics targeting AKR1C3, today announced a scientific presentation will be held for OBI-999 (anti-Globo H targeted ADC) at the World ADC Digital Scientific meeting on Sept 16, 2020. The scientific presentation titled, "A Novel Globo H-targeting Antibody-drug Conjugate: OBI 999" with a follow-up live discussion and question session will be l...

Read More

GSK, VIR USE CRISPR, ARTIFICIAL INTELLIGENCE TO FIND COVID-19 CURE

PharmaNewsIntelligence | April 07, 2020

news image

GSK is partnering with Vir Biotechnology to use CRISPR and artificial intelligence to identify anti-viral compounds that can treat coronaviruses, including COVID-19. GlaxoSmithKline (GSK) and Vir Biotechnology recently announced a collaboration to enhance COVID-19 drug discovery through the use of CRISPR and artificial intelligence.For more coronavirus updates, visit our resource page, updated twice daily by Xtelligent Healthcare Media. The partnership will initially focus on accelerating the de...

Read More

pharma news | January 14, 2020

news image

ROCHE AND ILLUMINA FORGE GENOMICS ALLIANCE FOR CANCER TESTING

Roche missed out on acquiring next-generation sequencing (NGS) specialist Illumina via a hostile takeover a few years back, but has compensated for that with a 15-year alliance focusing on cancer genomics. The new deal comes after Illumina called off a $1.2 billion merger agreement with another NGS player – Pacific Biosciences or PacBio – after concluding it would be unlikely to make it past antitrust regulators in the US and UK. Illumina is thought to have around 80% of the DNA sequ...

Read More

Managed Healthcare Executive | March 02, 2020

news image

POINT-OF-CARE TOOLS IN PHARMACY TAKE OFF

New point-of-care (POC) tools that promote communication between providers and patients are establishing themselves as next generation shared decision-making solutions, especially when it comes to medications and issues of insurance coverage, price, and out-of-pocket costs. “When compared to traditional shared decision-making tools, there’s an increased emphasis not just on improving measures such as medication adherence by involving the patient in his or her own care but also on usi...

Read More

OBI Pharma | September 14, 2020

news image

OBI PHARMA ANNOUNCES OBI-999 PRESENTATION AT 2020 WORLD ADC DIGITAL MEETING

OBI Pharma, Inc, a leader in Glycosphingolipid Immuno-Oncology therapeutics targeting the Globo Series antigens (Globo H and SSEA-4) and chemotherapeutics targeting AKR1C3, today announced a scientific presentation will be held for OBI-999 (anti-Globo H targeted ADC) at the World ADC Digital Scientific meeting on Sept 16, 2020. The scientific presentation titled, "A Novel Globo H-targeting Antibody-drug Conjugate: OBI 999" with a follow-up live discussion and question session will be l...

Read More

PharmaNewsIntelligence | April 07, 2020

news image

GSK, VIR USE CRISPR, ARTIFICIAL INTELLIGENCE TO FIND COVID-19 CURE

GSK is partnering with Vir Biotechnology to use CRISPR and artificial intelligence to identify anti-viral compounds that can treat coronaviruses, including COVID-19. GlaxoSmithKline (GSK) and Vir Biotechnology recently announced a collaboration to enhance COVID-19 drug discovery through the use of CRISPR and artificial intelligence.For more coronavirus updates, visit our resource page, updated twice daily by Xtelligent Healthcare Media. The partnership will initially focus on accelerating the de...

Read More